0QCV Abbvie Inc

 
 The Vanguard Group, Inc. ( IRSH) 
Form 8.3 - The Vanguard Group, Inc.: AbbVie plc 
 
07-May-2020 / 14:20 GMT/BST 
Dissemination of a Regulatory Announcement, transmitted by EQS Group. 
The issuer is solely responsible for the content of this announcement. 
 
              Ap19 
 
              FORM 8.3 
 
IRISH TAKEOVER PANEL 
******************** 
 
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER 
RULES, 2013 
****************************************************************************** 
******* 
 
DEALINGS BY PERSONS WITH IN INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% 
OR MORE 
****************************************************************************** 
****** 
 
1. KEY INFORMATION 
****************** 
 
Name of person dealing (Note 1)         The Vanguard Group, Inc. 
Company dealt in                        AbbVie plc 
Class of relevant security to which the US$0.01 common stock 
dealings being disclosed relate (Note 
2) 
Date of dealing                         06 May 2020 
 
2. INTERESTS AND SHORT POSITIONS 
 
(a) Interests and short positions (following dealing) in the class of relevant 
security dealt in (Note 3) 
 
                             Long                    Short 
                 Numbers    (%)                Numbers  (%) 
(1) Relevant     124,940,937          8.46%    39,403   0.00% 
securities 
(2) Derivatives 
(other than 
options) 
(3) Options and 
agreements to 
purchase/sell 
Total            124,940,937          8.46%    39,403   0.00% 
 
(b) Interests and short positions in relevant securities of the company, other 
than the class dealt in (Note 3) 
 
Class of relevant security:        Long              Short 
                             Numbers  (%)      Numbers  (%) 
(1) Relevant securities 
(2) Derivatives (other than 
options) 
(3) Options and agreements 
to purchase/sell 
Total 
 
Ap20 
 
1. Dealings (Note 4) 
 
(a) Purchases and sales 
 
Purchase/sale     Number of relevant       Price per unit (Note 
                      securities                    5) 
Sale          4,300                       84.87 USD 
Sale          40,750                      85.37 USD 
Purchase      7,139                       85.37 USD 
 
(b) Derivatives transactions (other than options transactions) 
 
Product name,  Nature of        Number of         Price per 
               transaction      relevant          unit 
                                securities 
 
e.g. CFD 
               (Note 6)                           (Note 5) 
                                (Note 7) 
Not Applicable 
 
(c) Options transactions in respect of existing relevant securities 
 
(i) Writing, selling, purchasing or varying 
 
Product   Writing, Number   Exercise  Type,  Expiry     Option 
name,     selling, of       price     e.g.   date       money 
          purchasi securiti           Americ            paid/rec 
          ng,      es to              an,               eived 
          varying  which              Europe            per unit 
e.g. call etc.     the                an                (Note 5) 
option             option             etc. 
                   relates 
                   (Note 7) 
Not 
Applicabl 
e 
 
(ii) Exercising 
 
Product name,    Number of securities Exercise price per unit 
                                      (Note 5) 
 
e.g. call option 
 
Not Applicable 
 
(e) Other dealings (including transactions in respect of new securities) (Note 
4) 
 
Nature of transaction Details Price per unit 
 
(Note 8)                      (if applicable) (Note 5) 
Not Applicable 
 
              Ap21 
 
2. OTHER INFORMATION 
 
Agreements, arrangements or understandings relating to options or derivatives 
 
Full details of any agreement, arrangement or understanding 
between the person disclosing and any other person relating to 
the voting rights of any relevant securities under any option 
referred to on this form or relating to the voting rights or 
future acquisition or disposal of any relevant securities to 
which any derivative referred to on this form is referenced. If 
none, this should be stated. 
 
Is a Supplemental Form 8 attached? (Note 9) NO 
 
Date of disclosure                              07 May 2020 
Contact name                                    Shawn Acker 
Telephone number                                001-610-669-8989 
If a connected EFM, name of offeree/offeror 
with which connected 
If a connected EFM, state nature of connection 
(Note 10) 
 
Category Code: RET - AbbVie plc 
TIDM:          IRSH 
LEI Code:      5493002789CX3L0CJP65 
Sequence No.:  62294 
EQS News ID:   1038815 
 
End of Announcement EQS News Service 
 
 

(END) Dow Jones Newswires

May 07, 2020 09:21 ET (13:21 GMT)

Abbvie (LSE:0QCV)
Gráfico Histórico do Ativo
De Fev 2025 até Mar 2025

Abbvie (LSE:0QCV)
Gráfico Histórico do Ativo
De Mar 2024 até Mar 2025